OCUL Reports $126M Q1 Revenue, $0.08 EPS, SOL-1 Wet AMD Phase 3 Superiority Trial Positive, AXPAXLI NDA Submission Planned, $666.7M Cash Runway to 2028
Ocular Therapeutix, Inc. · PHARMACEUTICAL PREPARATIONS · Now $8.93
-2.2% in 7d after detection
Post-detection moves
1h
—
1d
0.0%
3d
-0.6%
7d
-2.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS